Anti-Aquaporin 4 (AQP4), Serum
Use
This test is used for evaluation of patients with suspected Neuromyelitis Optica Spectrum Disorder (NMOSD).
Special Instructions
Testing for Neuromyelitis Optica Spectrum should be considered in patients presenting with optic neuritis, transverse myelitis, and/or area postrema clinical syndrome, which consists of intractable hiccups or nausea and vomiting. Retesting should be considered before initiating B-cell- or antibody-targeted therapies.
Limitations
The absence of AQP4 antibodies does not rule out NMOSD due to possible false-negatives, particularly if the patient is under immunosuppressive therapy. Antibody levels might increase during relapse and decrease with therapy; however, titer changes may not predict clinical relapses. Results should not inform diagnosis without confirmation from other diagnostic methods. This test's performance characteristics were established by LabCorp and have not been approved by the FDA.
Methodology
Immunoassay (Immunofluorescence)
Biomarkers
LOINC Codes
- 95272-1
- 95272-1
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
Serum from red-top tube
Storage Instructions
Room temperature
Causes for Rejection
Gross hemolysis; grossly lipemic; serum separator tube (SST)
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |